PMID- 25855920
OWN - NLM
STAT- MEDLINE
DCOM- 20151116
LR  - 20181202
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 19
IP  - 6
DP  - 2015
TI  - Effects of pioglitazone and glipizide on platelet function in patients with type 
      2 diabetes.
PG  - 963-70
LID - 8679 [pii]
AB  - OBJECTIVE: Platelet hyper-reactivity is one of the most important causes of 
      accelerated atherosclerosis and increased risk of thrombotic vascular events 
      associated with type 2 diabetes mellitus (T2DM). This study aimed to investigate 
      the effects of different add-on anti-diabetic therapies on platelet function in 
      T2DM patients. PATIENTS AND METHODS: A three-group parallel study was conducted 
      in 120 patients with T2DM (HbA1c > 7%) undergoing treatment with metformin. 
      Patients were randomly assigned to receive add-on therapy with glipizide or 
      pioglitazone. Markers of PF (platelet PAC-1 binding, p-selectin expression and 
      adenosine diphosphate-induced platelet aggregation) were measured at weeks 0, 4 
      and 24. Primary outcome was effects of pioglitazone and glipizide on platelet 
      aggregation. Secondary outcome was the related influencing factors of platelet 
      aggregation. RESULTS: There were no significant differences in baseline 
      characteristics between glipizide and pioglitazone groups. After 24 weeks, 
      fasting blood glucose (p < 0.01) and HbA1c (p < 0.01) were higher in pioglitazone 
      group than those in glipizide group. Fasting insulin (p < 0.01) and HOMA-IR (p < 
      0.01) were lower in pioglitazone group than that in glipizide group. Markers of 
      platelet function were significantly decreased in both groups at 24 weeks (PAC-1: 
      pioglitazone: -63.3%; glipizide: -45.9%; p-selectin: pioglitazone: -73.9%; 
      glipizide: -54.9%; platelet aggregation: pioglitazone: -24.1%; glipizide: -13.4%; 
      all p < 0.01 vs. baseline), but the decrease in platelet function was more 
      significant in pioglitazone group (p < 0.05). Multiple linear regression analyses 
      showed that platelet aggregation was independently associated with treatment 
      groups (p < 0.001), Triglyceride (p = 0.009) and HDL-C (p = 0.015). CONCLUSIONS: 
      Add-on therapy with pioglitazone may be more effective than glipizide for 
      inhibiting platelet activation in T2DM.
FAU - Xiao, C-C
AU  - Xiao CC
AD  - Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui 
      Medical University, Hefei, Anhui Province, China. ysd196406@163.com.
FAU - Ren, A
AU  - Ren A
FAU - Yang, J
AU  - Yang J
FAU - Ye, S-D
AU  - Ye SD
FAU - Xing, X-N
AU  - Xing XN
FAU - Li, S-M
AU  - Li SM
FAU - Chen, C
AU  - Chen C
FAU - Chen, R-P
AU  - Chen RP
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - X4OV71U42S (Pioglitazone)
RN  - X7WDT95N5C (Glipizide)
SB  - IM
MH  - Blood Platelets/drug effects/*physiology
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Glipizide/*administration & dosage
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Pioglitazone
MH  - Platelet Activation/drug effects/physiology
MH  - Thiazolidinediones/*administration & dosage
MH  - Treatment Outcome
EDAT- 2015/04/10 06:00
MHDA- 2015/11/17 06:00
CRDT- 2015/04/10 06:00
PHST- 2015/04/10 06:00 [entrez]
PHST- 2015/04/10 06:00 [pubmed]
PHST- 2015/11/17 06:00 [medline]
AID - 8679 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2015;19(6):963-70.